<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582254</url>
  </required_header>
  <id_info>
    <org_study_id>AOR14101</org_study_id>
    <secondary_id>2014-002597-37</secondary_id>
    <nct_id>NCT03582254</nct_id>
  </id_info>
  <brief_title>Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years</brief_title>
  <acronym>LOCALYSE</acronym>
  <official_title>Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients older than 60 years account for half of cases of Primary Central Nervous System&#xD;
      Lymphoma (PCNSL) and have a poorer outcome. No prognostic or predictive factors exist for&#xD;
      survival after initial remission. 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose -&#xD;
      Positron Emission Tomography ([18F]FDG-PET) plays a key role in grading and therapy&#xD;
      monitoring of systemic diffuse large B-cell type.&#xD;
&#xD;
      LOCALYZE is an ancillary Positron Emission Tomography / Magnetic Resonance (PET/MR) clinical&#xD;
      study from BLOCAGE 01 (Pr Hoang-Xuan). The aim is to evaluate the usefulness of [18F]FDG-PET&#xD;
      to monitor treatment response in PCNSL older than 60 years (n=56), in complement to&#xD;
      multiparametric Magnetic Resonance Imaging (MRI).&#xD;
&#xD;
      Hypothesis The investigators assume that the development of new imaging biomarker extracted&#xD;
      from PET imaging and multiparametric MRI, could improve the assessment of treatment response&#xD;
      in PCNSL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière&#xD;
      Hospital:&#xD;
&#xD;
        -  prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine&#xD;
           and cytarabine) (PET#1),&#xD;
&#xD;
        -  after two chemotherapy cycles (PET#2),&#xD;
&#xD;
        -  at the end of the first-line chemotherapy regimens (PET#3).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2016</start_date>
  <completion_date type="Anticipated">May 12, 2023</completion_date>
  <primary_completion_date type="Actual">May 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival calculated from the date of completion of the end of chemotherapy PET</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the predictive value of [18F]FDG-PET assessment performed at the end-of-treatment (high-dose methotrexate based polychemotherapy), on progression free survival in newly diagnosed PCNSL with age ≥60 years (n=56).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>[18F]-FDG PET/MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]-FDG PET/MR</intervention_name>
    <description>[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:&#xD;
prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),&#xD;
after two chemotherapy cycles (PET#2),&#xD;
at the end of the first-line chemotherapy regimens (PET#3).</description>
    <arm_group_label>[18F]-FDG PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed primary cerebral lymphoma&#xD;
&#xD;
          -  Age ≥60 years&#xD;
&#xD;
          -  Pathology proven diagnosis or positive cytology of the Cerebrospinal Fluid (CSF) or&#xD;
             vitreous&#xD;
&#xD;
          -  Karnofsky Performance Status ≥40&#xD;
&#xD;
          -  No evidence of systemic Non-Hodgkin lymphomas (NHL) (body CT scan, bone marrow biopsy)&#xD;
&#xD;
          -  Adequate haematological, renal and hepatic function&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 40 ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled diabetes with fasting glycaemia &gt; 200 mg/dL&#xD;
&#xD;
          -  Sensitivity to active substance in [18F]-FDG&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 40 ml/min&#xD;
&#xD;
          -  No contraindication to MRI (magnetic resonance imaging)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

